New Phase 2 Trial to Test NYX-2925 as Potential Fibromyalgia Therapy

New Phase 2 Trial to Test NYX-2925 as Potential Fibromyalgia Therapy
A new Phase 2 clinical trial will continue to assess the safety and effectiveness of the non-opioid small molecule candidate therapy NYX-2925, developed by Aptinyx, in fibromyalgia patients. NYX-2925 is an oral therapy that modulates the NMDA receptor, which is key in neuronal communication and is involved in regulating pain signals in the brain and spinal cord. NYX-2925 alters neural cell communication, and is seen as a potential therapy to lessen pain and other symptoms associated with chronic pain. In preclinical models of different neuropathic pain conditions, NYX-2925 showed robust effectiveness, and a favorable safety profile. Data from a subsequent Phase 1 trial (NCT02834741) with healthy individuals, showed NYX-2925 was well-tolerated across a wide range of doses. A previous Phase 2 trial (NCT03249103) that tested daily oral treatment with 20 mg and 200 mg of NYX-2925, as well as a placebo, over six weeks. Results  showed that NYX-2925
Subscribe or to access all post and page content.